A Phase 2 interventional study of Live attenuated Japanese encephalitis virus; Yellow fever virus and Yellow fever virus; Live attenuated Japanese encephalitis virus in Japanese Encephalitis and Yellow Fever, sponsored by Sanofi. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-09-20.
Sponsored by Sanofi · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Encephalitis, Japanese by Sanofi — none open to participants now, none under way, none of them phase 3. Encephalitis, Japanese · Sanofi.
Among the 18 studies in Encephalitis, Japanese by Sanofi, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2004, is one of 6 in phase 2, and was the 7th registered.
74 studies on the registry are indexed under Encephalitis, Japanese; 3 are open to participants now.
Browse Encephalitis, Japanese studies →None of the 18 studies in Encephalitis, Japanese by Sanofi is open now. The open studies under Encephalitis, Japanese, anywhere →
Of the 2 Encephalitis, Japanese studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2004.
This study's enrollment of 108 is below the median of 300 across 65 interventional studies indexed under Encephalitis, Japanese.
Median enrollment 300 across the 17 interventional studies, 50 across the 1 observational. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Encephalitis, Japanese by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to obtain safety, tolerability, and immunogenicity data on the co-administration or sequential administration of Chimeravax™-JE vaccine and STAMARIL®.
Objectives:
Safety:
Immunogenicity:
All participants will receive two injections, one to each arm on Days 0 and 30, respectively. Immunogenicity will be tested on Days 0, 15, 30, 45, and 60, and at Month 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ChimeriVax™-JE on Day 0 and STAMARIL® on Day 30
Biological: Live attenuated Japanese encephalitis virus; Yellow fever virus
Participants will receive STAMARIL® on Day 0 and ChimeriVax™-JE on Day 30
Biological: Yellow fever virus; Live attenuated Japanese encephalitis virus
Participants will receive ChimeriVax™-JE and STAMARIL® on Day 0 and diluent on Day 30.
Biological: Live attenuated Japanese encephalitis virus; Yellow fever virus
Participants will receive Diluent on Day 0 and ChimeriVax™-JE and STAMARIL® on Day 30.
Biological: Live attenuated Japanese encephalitis virus; Yellow fever virus
ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
Also known as: ChimeriVax-JE, STAMARIL®
STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
Also known as: STAMARIL®, ChimeriVax™-JE
ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
Also known as: ChimeriVax™-JE, STAMARIL®
Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
Also known as: ChimeriVax™-JE, STAMARIL®
Number of Participants With Japanese Encephalitis Seroconversion Following ChimeriVax™-JE or STAMARIL® Alone or the Co-administration of ChimeriVax™-JE and STAMARIL®, or Placebo Vaccination.
Neutralising antibody titer against homologous Japanese encephalitis (JE), yellow fever (YF), and other relevant wild type JE strains were determined using a 50% serum dilution plaque reduction neutralisation test. Seroconversion post-vaccination was defined as the appearance of neutralising antibody titer when not present at Day 0, or at least a four-fold rise in neutralising antibody titer between the pre-vaccination (Day 0) and the post-vaccination samples. The 30 Days post-JE seroconversion is: Day 30 for Group 1 (ChimeriVax™-JE then STAMARIL®) and Group 3 (Co-administration of ChimeriVax™-JE and STAMARIL, then Diluent); Day 60 for Group 2 (STAMARIL® then ChimeriVax™-JE) and Group 4 (Diluent then Co-administration of ChimeriVax™-JE and STAMARIL).
Time frame: Pre-vaccination (Day 0 or 30) and post-vaccination (Day 30 or 60)
Number of Participants With Yellow Fever Seroconversion Following ChimeriVax™-JE or STAMARIL® Alone or the Co-administration of ChimeriVax™-JE and STAMARIL® or Placebo Vaccination.
Neutralising antibody titer against yellow fever strains was determined using a 50% serum dilution plaque reduction neutralisation test. Seroconversion at a later post vaccination timepoint ws defined as the appearance of neutralising antibody titer when not present at Day 0, or at least a four-fold rise in neutralising antibody titre between the pre-injection Day 0 and later post vaccination samples. The Day 30 post-JE seroconversion is: Day 30 for Group 1 (ChimeriVax™-JE then STAMARIL®) and Group 3 (Co-administration of ChimeriVax™-JE and STAMARIL, then Diluent); Day 60 for Group 2 (STAMARIL® then ChimeriVax™-JE) and Group 4 (Diluent then Co-administration of ChimeriVax™-JE and STAMARIL).
Time frame: Pre-vaccination (Day 0 or 30) and post-vaccination (Day 30 or 60)
Number of Participants Who Seroconverted to Japanese Encephalitis 30 Days Post ChimeriVax™-JE Vaccination
Neutralising antibody titer against homologous JE, YF, and other relevant wild type JE strains was determined using a 50% serum dilution plaque reduction neutralisation test. Seroconversion at a later post vaccination timepoint was defined as the appearance of neutralising antibody titer when not present at Day 0, or at least a four-fold rise in neutralising antibody titer between the pre-injection Day 0 and post-vaccination samples.
Time frame: Day 0 (Pre-vaccination) through Day 30 post-vaccination
Number of Participants Reporting Solicited Local and Systemic Adverse Events Post Vaccination With ChimeriVax™-JE or STAMARIL® Alone or the Co-Administration of ChimeriVax™-JE and STAMARIL®, or Placebo
Solicited Local Adverse Events: Injection Site Pain, Erythema, Swelling, Hemorrhage, Venipuncture site Hemorrhage. Solicited Systemic Adverse Events: Fatigue, Malaise, Pyrexia, Chills, Headache, Dizziness, Myalgia, Abdominal Pain, Diarrhea, Nausea, Pharyngolaryngeal Pain. All solicited local reactions associated with ChimeriVax™-JE are presented in Group 1, those associated with STAMARIL® in Group 2, those associated with co-administered vaccines in Group 3, and those associated with diluent in Group 4. The solicited systemic adverse events are reported according to the participants' randomized study groups.
Time frame: Day 0 up to Day 60 post-vaccination
Geometric Mean Titers (GMTs) to Japanese Encephalitis (Homologous Virus) Following ChimeriVax™-JE or STAMARIL® Alone or the Co-administration of ChimeriVax™-JE and STAMARIL®, or Placebo Vaccination.
Neutralising antibody titer against homologous Japanese encephalitis (JE) and other relevant wild type JE strains was determined using a 50% serum dilution plaque reduction neutralisation test. Post-vaccination 15 (30) Days JE seroconversion is: Day 15 (30) for Group 1 (ChimeriVax™-JE then STAMARIL®) and Group 3 (Co-administration of ChimeriVax™-JE and STAMARIL, then Diluent); Day 45 (60) for Group 2 (STAMARIL® then ChimeriVax™-JE) and Group 4 (Diluent then Co-administration of ChimeriVax™-JE and STAMARIL)
Time frame: Day 0 through 6 months post-vaccination
Geometric Mean Titers to Yellow Fever (Homologous Virus) Following ChimeriVax™-JE or STAMARIL® Alone or the Co-administration of ChimeriVax™-JE and STAMARIL®, or Placebo
Neutralising antibody titer against homologous yellow fever was determined using a 50% serum dilution plaque reduction neutralisation test. Post vaccination 15 (30) Days Yellow Fever seroconversion is: Day 15 (30) for Group 1 (ChimeriVax™-JE then STAMARIL®) and Group 3 (Co-administration of ChimeriVax™-JE and STAMARIL, then Diluent); Day 45 (60) for Group 2 (STAMARIL® then ChimeriVax™-JE) and Group 4 (Diluent then Co-administration of ChimeriVax™-JE and STAMARIL).
Time frame: Day 0 through 6 months post-vaccination
Participants were screened and enrolled from 27 July 2004 to 27 September 2004 at 1 clinical center in Australia.
| Milestone | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® |
|---|---|---|---|---|
| Started | 36 | 36 | 18 | 18 |
| Completed | 36 | 35 | 18 | 17 |
| Not completed | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
Neutralising antibody titer against homologous Japanese encephalitis (JE), yellow fever (YF), and other relevant wild type JE strains were determined using a 50% serum dilution plaque reduction neutralisation test. Seroconversion post-vaccination was defined as the appearance of neutralising antibody titer when not present at Day 0, or at least a four-fold rise in neutralising antibody titer between the pre-vaccination (Day 0) and the post-vaccination samples. The 30 Days post-JE seroconversion is: Day 30 for Group 1 (ChimeriVax™-JE then STAMARIL®) and Group 3 (Co-administration of ChimeriVax™-JE and STAMARIL, then Diluent); Day 60 for Group 2 (STAMARIL® then ChimeriVax™-JE) and Group 4 (Diluent then Co-administration of ChimeriVax™-JE and STAMARIL).
| Participants | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL, Then Diluent | Diluent Then Coadministration With ChimeriVax™-JE and STAMARIL |
|---|---|---|---|---|
| Day 30 (N = 17, 23, 13, 10) | 17 | 2 (0 to 0) | 12 | 0 |
| Day 60 (N = 17, 23, 13, 10) | 17 | 21 | 12 | 10 |
| 30 Days Post-JE Seroconversion (N = 17, 23, 23, 0) | 17 | 21 | 22 | NA |
Neutralising antibody titer against yellow fever strains was determined using a 50% serum dilution plaque reduction neutralisation test. Seroconversion at a later post vaccination timepoint ws defined as the appearance of neutralising antibody titer when not present at Day 0, or at least a four-fold rise in neutralising antibody titre between the pre-injection Day 0 and later post vaccination samples. The Day 30 post-JE seroconversion is: Day 30 for Group 1 (ChimeriVax™-JE then STAMARIL®) and Group 3 (Co-administration of ChimeriVax™-JE and STAMARIL, then Diluent); Day 60 for Group 2 (STAMARIL® then ChimeriVax™-JE) and Group 4 (Diluent then Co-administration of ChimeriVax™-JE and STAMARIL).
| Participants | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® |
|---|---|---|---|---|
| Day 30 (N = 17, 23, 13, 10) | 0 | 23 | 13 | 1 |
| Day 60 (N = 17, 23, 13, 10) | 17 | 23 | 13 | 10 |
| Day 30 Post-JE Seroconversion (N = 17, 23, 23, 0) | 17 | 23 | 23 | NA |
Neutralising antibody titer against homologous Japanese encephalitis (JE) and other relevant wild type JE strains was determined using a 50% serum dilution plaque reduction neutralisation test. Post-vaccination 15 (30) Days JE seroconversion is: Day 15 (30) for Group 1 (ChimeriVax™-JE then STAMARIL®) and Group 3 (Co-administration of ChimeriVax™-JE and STAMARIL, then Diluent); Day 45 (60) for Group 2 (STAMARIL® then ChimeriVax™-JE) and Group 4 (Diluent then Co-administration of ChimeriVax™-JE and STAMARIL)
| Titers | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® |
|---|---|---|---|---|
| 15 Days Post-vaccination (N = 17, 23, 13, 10) | 282.1 (130.8 to 608.3) | 140.2 (50.9 to 386.3) | 119.9 (53.6 to 267.9) | 386.5 (135.1 to 1106.4) |
| 30 Days Post-vaccination (N = 17, 23, 13, 10) | 1461.6 (632.8 to 3375.8) | 426.4 (172.3 to 1055.1) | 221.2 (94.9 to 515.3) | 611.6 (188.4 to 1986.0) |
| 45 Days Post-vaccination (N = 17, 0, 13, 0) | 1099.3 (465.9 to 2593.6) | NA (NA to NA) | 146.3 (58.3 to 367.2) | NA (NA to NA) |
| 60 Days Post-vaccination (N = 17, 0, 13, 0) | 687.8 (315.4 to 1499.8) | NA (NA to NA) | 103.1 (43.9 to 242.1) | NA (NA to NA) |
| 6 Months Post-vaccination (N = 16, 22, 13, 10) | 267.5 (122.4 to 584.4) | 134.0 (59.2 to 303.4) | 94.6 (37.8 to 236.9) | 99.9 (56.8 to 175.7) |
Neutralising antibody titer against homologous yellow fever was determined using a 50% serum dilution plaque reduction neutralisation test. Post vaccination 15 (30) Days Yellow Fever seroconversion is: Day 15 (30) for Group 1 (ChimeriVax™-JE then STAMARIL®) and Group 3 (Co-administration of ChimeriVax™-JE and STAMARIL, then Diluent); Day 45 (60) for Group 2 (STAMARIL® then ChimeriVax™-JE) and Group 4 (Diluent then Co-administration of ChimeriVax™-JE and STAMARIL).
| Titers | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® |
|---|---|---|---|---|
| Day 15 Post-vaccination (N = 17, 23, 13, 10) | 463.1 (156.2 to 1372.8) | 1080.7 (606.3 to 1926.2) | 1150.0 (527.3 to 2507.8) | 2044.1 (768.7 to 5435.2) |
| Day 30 Post-vaccination (N = 17, 23, 13, 10) | 3288.5 (1415.4 to 7640.4) | 3704.6 (2271.4 to 6042.0) | 1565.6 (897.9 to 2729.9) | 3054.9 (1230.2 to 7586.3) |
| Day 45 Post-vaccination (N = 0, 23, 13, 0) | NA (NA to NA) | 2442.5 (1450.5 to 4112.8) | 974.6 (572.3 to 1659.8) | NA (NA to NA) |
| Day 60 Post-vaccination (N = 0, 23, 13, 0) | NA (NA to NA) | 2175.1 (1223.9 to 3865.4) | 653.1 (277.2 to 1539.0) | NA (NA to NA) |
| 6 Months Post-vaccination (N = 16, 22, 13, 10) | 2017.5 (842.0 to 4834.3) | 2058.7 (1302.5 to 3253.8) | 947.4 (431.3 to 2081.3) | 1351.8 (534.9 to 3416.4) |
Neutralising antibody titer against homologous JE, YF, and other relevant wild type JE strains was determined using a 50% serum dilution plaque reduction neutralisation test. Seroconversion at a later post vaccination timepoint was defined as the appearance of neutralising antibody titer when not present at Day 0, or at least a four-fold rise in neutralising antibody titer between the pre-injection Day 0 and post-vaccination samples.
| Participants | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® |
|---|---|---|---|---|
| JE Homologous Virus | 17 | 21 | 12 | 10 |
| Genotype I | 17 | 21 | 13 | 10 |
| Genotype II | 15 | 16 | 9 | 9 |
| Genotype III | 16 | 20 | 9 | 10 |
| Genotype IV | 15 | 15 | 5 | 9 |
Solicited Local Adverse Events: Injection Site Pain, Erythema, Swelling, Hemorrhage, Venipuncture site Hemorrhage. Solicited Systemic Adverse Events: Fatigue, Malaise, Pyrexia, Chills, Headache, Dizziness, Myalgia, Abdominal Pain, Diarrhea, Nausea, Pharyngolaryngeal Pain. All solicited local reactions associated with ChimeriVax™-JE are presented in Group 1, those associated with STAMARIL® in Group 2, those associated with co-administered vaccines in Group 3, and those associated with diluent in Group 4. The solicited systemic adverse events are reported according to the participants' randomized study groups.
| Participants | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® |
|---|---|---|---|---|
| Injection Site Pain (N = 71, 72, 36, 36) | 13 | 13 | 6 | 4 |
| Injection Site Erythema (N = 71, 72, 36, 36) | 6 | 9 | 3 | 1 |
| Injection Site Swelling (N = 71, 72, 36, 36) | 4 | 0 | 3 | 1 |
| Injection Site Hemorrhage (N = 71, 72, 36, 36) | 1 | 2 | 1 | 0 |
| Venipuncture Site Hemorrhage (N = 71, 72, 36, 36) | 0 | 2 | 0 | 0 |
| Fatigue (N = 36, 36, 18, 18) | 16 | 15 | 3 | 10 |
| Malaise (N = 36, 36, 18, 18) | 10 | 12 | 2 | 6 |
| Pyrexia (N = 36, 36, 18, 18) | 3 | 4 | 0 | 3 |
| Chills (N = 36, 36, 18, 18) | 1 | 4 | 1 | 2 |
| Headache (N = 36, 36, 18, 18) | 18 | 20 | 6 | 8 |
| Dizziness (N = 36, 36, 18, 18) | 0 | 2 | 0 | 0 |
| Myalgia (N = 36, 36, 18, 18) | 7 | 12 | 3 | 4 |
| Abdominal Pain (N = 36, 36, 18, 18) | 5 | 4 | 2 | 3 |
| Diarrhea (N = 36, 36, 18, 18) | 7 | 2 | 2 | 3 |
| Nausea (N = 36, 36, 18, 18) | 3 | 1 | 1 | 2 |
| Pharyngolaryngeal Pain (N = 36, 36, 18, 18) | 0 | 2 | 0 | 1 |
Collected over Adverse events data were collected from Day 0, after vaccination up to Month 6 post-vaccination.. Non-serious events are listed at a 5.00% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ChimeriVax™-JE Then STAMARIL® | — | 0/36 (0%) | 18/71 (25.4%) |
| STAMARIL® Then ChimeriVax™-JE | — | 0/36 (0%) | 20/72 (27.8%) |
| Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | — | 0/18 (0%) | 6/36 (16.7%) |
| Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® | — | 0/18 (0%) | 10/36 (27.8%) |
| Event | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® |
|---|---|---|---|---|
| FatigueGeneral disorders | 16/36 | 15/36 | 3/18 | 10/18 |
| HeadacheNervous system disorders | 18/36 | 20/36 | 6/18 | 8/18 |
| MalaiseGeneral disorders | 10/36 | 12/36 | 2/18 | 6/18 |
| MyalgiaMusculoskeletal and connective tissue disorders | 7/36 | 12/36 | 3/18 | 4/18 |
| DiarrheaGastrointestinal disorders | 7/36 | 2/36 | 2/18 | 3/18 |
| Injection Site PainGeneral disorders | 13/71 | 13/72 | 6/36 | 4/36 |
| PyrexiaGeneral disorders | 3/36 | 4/36 | 0/18 | 3/18 |
| Abdominal PainGastrointestinal disorders | 5/36 | 4/36 | 2/18 | 3/18 |
| Injection Site ErythemaGeneral disorders | 6/71 | 9/72 | 3/36 | 1/36 |
| ChillsGeneral disorders | 1/36 | 4/36 | 1/18 | 2/18 |
| Age, Categorical(Participants) | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 36 | 36 | 18 | 18 | 108 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age Continuous(Years) | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® | Total |
|---|---|---|---|---|---|
| Mean | 27.2 ± 9.71 | 23.4 ± 6.95 | 27.5 ± 10.19 | 25.8 ± 8.26 | 25.8 ± 8.77 |
| Sex: Female, Male(Participants) | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® | Total |
|---|---|---|---|---|---|
| Female | 16 | 13 | 10 | 7 | 46 |
| Male | 20 | 23 | 8 | 11 | 62 |
| Region of Enrollment(Participants) | ChimeriVax™-JE Then STAMARIL® | STAMARIL® Then ChimeriVax™-JE | Co-administration of ChimeriVax™-JE and STAMARIL® Then Diluent | Diluent Then Coadministration With ChimeriVax-JE and STAMARIL® | Total |
|---|---|---|---|---|---|
| Australia | 36 | 36 | 18 | 18 | 108 |
The record gives a start of Jul 2004, a primary completion of Apr 2005 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 7 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Yellow Fever Vaccine